Press release from Sen. Mike Crapo: Crapo, Republican Senators Seek Explanation, Urge Reconsideration of Changes to Kratom-Derived Scheduling
Press release from Sen. Mike Crapo (R-Idaho), published Nov. 18, 2026. These are the senator's own words, not the paper's reporting; cut for length only.
U.S. Senator Mike Crapo (R-Idaho) joined Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) and six Republican Senators in a letter urging the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) to explain and reconsider proposed changes to the emergency scheduling order for semi-synthetic, kratom-derived substances, including 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MP).
However, in October, the DEA reversed course, issuing a revised proposal that doubled the original threshold established for 7-OH and removed MP from Schedule I.
“Kratom is a drug in any form with addictive properties, and we believe this combined threshold level for 7-OH and MP set by DEA is inappropriately high and unsound… If the administration’s goal is to remove all unsafe products from the shelves, particularly synthetic or enhanced kratom products, this order misses the mark,” the lawmakers wrote.
Crapo and Grassley are joined on the letter by Senators Jim Risch (R-Idaho)…
Source: Press release from Sen. Mike Crapo, Nov. 18, 2026 (cut for length).